Small Cell Lung Cancer Clinical Trials

43 studies are recruiting for small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Tempus Small Cell Lung Cancer Observational Study (Sculptor)

   The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line trea…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Colorado, Aurora, Colorado

   Locations

   11 in total

   Run by

   Tempus AI

   See if you can join NCT05257551 on ClinicalTrials.gov

2. A Study of Hospital-at-Home for People Receiving Tarlatamab

   The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06957314 on ClinicalTrials.gov

3. A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

   The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05419076 on ClinicalTrials.gov

4. Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

   This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT05800587 on ClinicalTrials.gov

5. Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

   This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   7 in total

   Run by

   Advenchen Pharmaceuticals, LLC.

   See if you can join NCT05363280 on ClinicalTrials.gov

6. MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

   This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks f…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Locations

   4 in total

   Run by

   Hirva Mamdani

   See if you can join NCT05903092 on ClinicalTrials.gov

7. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

8. Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

   The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated with standard therapies. The main goals of the study are to understand how safe SYS6043 is, what side effects it may caus…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   BRCR Global, Plantation, Florida

   Locations

   5 in total

   Run by

   Conjupro Biotherapeutics, Inc.

   See if you can join NCT07424547 on ClinicalTrials.gov

9. Study of Trilaciclib and Lurbinectidin

   Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina

   Locations

   2 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT05578326 on ClinicalTrials.gov

10. Phase 2 Study of Fingolimod in Lung Cancers

    This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for eff…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina

    Run by

    Medical University of South Carolina

    See if you can join NCT06424067 on ClinicalTrials.gov

11. Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

    This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (ra…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Medicine, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Chicago

    See if you can join NCT05068232 on ClinicalTrials.gov

12. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

13. Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

    This phase II clinical trial will study the safety and efficacy of onvansertib to treat patients with small cell lung cancer (SCLC) who have either not responded to or are unable to tolerate chemotherapy. Onvansertib is a drug that inhibits polo-like kinase 1 (PLK-1), an enzyme that is over-express…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

    Locations

    2 in total

    Run by

    University of Maryland, Baltimore

    See if you can join NCT05450965 on ClinicalTrials.gov

14. 7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)

    Comparison of a 7t MRI to standard of care 1.5t/3t MRI scans to determine if earlier detection of brain metastases are possible on a 7t.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Missouri, Columbia, Missouri

    Run by

    University of Missouri-Columbia

    See if you can join NCT07175077 on ClinicalTrials.gov

15. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Michigan Hospitals, Ann Arbor, Michigan

    Locations

    5 in total

    Run by

    Novelty Nobility, Inc.

    See if you can join NCT06805825 on ClinicalTrials.gov

16. A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

    This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recomm…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Zelgen Site 102, Plantation, Florida

    Locations

    6 in total

    Run by

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    See if you can join NCT06592638 on ClinicalTrials.gov

17. Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)

    The goal of this observational study is to understand how genomic and epigenetic factors contribute to resistance against chemo-immunotherapy in adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine carcinoma (LCNEC). Both ES-SCLC and LCNEC a…

    Stage

    Not phased

    Ages

    18 to 85

    Site

    3rd Department of Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens,

    Locations

    2 in total

    Run by

    Oncology Center of Biochemical Education And Research

    See if you can join NCT06717243 on ClinicalTrials.gov

18. A Multicenter Cancer Biospecimen Collection Study

    This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent st…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Curebase, San Francisco, California

    Run by

    Cofactor Genomics, Inc.

    See if you can join NCT04510129 on ClinicalTrials.gov